Excellent - I now have all the images and information needed. Here is the comprehensive IPCL pattern guide:
IPCL (Intraepithelial Papillary Capillary Loop) Pattern Classification - Esophagus
What is IPCL?
The IPCL is a capillary that arises from the fourth branch of the arborescent subepithelial vessels, forms single loops within the epithelial papillae, and is visible under magnifying NBI endoscopy (ME-NBI). In normal squamous epithelium, IPCLs are regular, small, and uniform. With progressive neoplastic transformation, they undergo stepwise morphological changes in four parameters:
D - T - C - V: Dilation | Tortuosity | Change in Caliber | Variation in shape
Classification Systems
Two main classifications are in use:
| Inoue (Original 2001) | JES Classification (2017) |
|---|
| Basis | 5 types (I-VN) | 2 types (A and B) |
| Clinical use | Japan, academic | Current international standard |
Inoue IPCL Classification (Original)
Below is the full Inoue classification showing endoscopic images, schematics, pathological correlation, and treatment implication:
From Bailey & Love's Short Practice of Surgery, 28th Ed., Fig. 66.45 - IPCL classification showing depth of invasion and treatment indication
Type-by-Type Breakdown (Inoue)
| Type | Morphology | Histology / Depth | Treatment |
|---|
| Type I | Normal regular loops; small, uniform, hairpin shape | Normal squamous epithelium | None |
| Type II | Elongation + mild dilation | Esophagitis / reactive change | None / treat inflammation |
| Type III | Increased elongation, mild caliber change | Inflammation / Low-grade intraepithelial neoplasia (LGIN) | Observe / endoscopic treatment |
| Type IV | Increased caliber + elongation toward epithelial surface | Borderline HGIN / definite carcinoma | Endoscopic treatment |
| Type V-1 | 4 features: dilation + tortuosity + irregular caliber + non-uniformity (loop intact) | Carcinoma in situ (M1, EP) | EMR/ESD |
| Type V-2 | V-1 features + elongation in vertical plane | M2 (lamina propria invasion, LPM) | EMR/ESD |
| Type V-3 | Horizontal spread + loss of loop arrangement (destruction of IPCL) | M3/SM1 (muscularis mucosa/superficial submucosa) | ESD (relative indication); surgery if SM suspected |
| Type VN | Vessel diameter ~3x Type V-3; new tumor vessel formation | SM2 or deeper (deep submucosal) | Surgery |
JES Classification (Japan Esophageal Society, 2017) - Current Standard
The JES classification simplifies Inoue into a more clinically actionable 2-tier system:
JES Classification: Type A (normal), B1 (loop present), B2 (loop lost), B3 (highly dilated)
JES Type A - Normal/Benign
- Normal IPCL OR abnormal microvessels without severe irregularity (3 or fewer morphological factors)
- Vessel caliber: 7-10 µm
- Corresponds to: Normal epithelium, inflammation, LGIN
- No invasion
JES Type B - Abnormal (subdivided)
Morphological factors for "severe irregularity" = ALL 4 of: tortuosity + dilation + irregular caliber + various shapes
| Subtype | Description | Caliber | Depth | Histology |
|---|
| B1 | Abnormal microvessels with severe irregularity + loop-like formation preserved | ~20 µm | T1a (EP or LPM) = M1/M2 | HGIN, invasive SCC |
| B2 | Type B vessels + loss of loop-like formation | Variable | T1a (MM) or T1b (SM1) = M3/SM1 | Invasive SCC |
| B3 | Highly dilated vessels; caliber >3x that of B2 | >60 µm | T1b (SM2) or deeper | Invasive SCC |
Clinical Endoscopic Images
Below are actual endoscopic images showing early squamous cell cancer detected with NBI:
Fig. 66.44 from Bailey & Love's - (a) White light: suspicious lesion with white arrows; (b) NBI near-focus: abnormal IPCLs visible; (c) Lugol's chromoendoscopy: lesion unstained (iodine-negative)
Inoue + JES Correlation (Summary Diagram)
The comprehensive figure below shows both Inoue (original) and JES classifications side by side with endoscopic images, schematics, pathology, and treatment indication:
(A) Inoue classification; (B) Arima classification; (C) JES classification with vessel calibers. Note: shaded oval = "formation of area" (loss of individual loop structure)
Key Points for Clinical Practice
1. When to use ME-NBI:
- Any reddish or discolored flat lesion on white light
- Lugol's iodine-negative (LCL) areas
- Screening in high-risk patients (alcohol + smoking)
2. Treatment decision algorithm:
Type A / IPCL I-III → Observe or treat inflammation
IPCL IV / JES B1 → EMR or ESD (curative)
JES B2 / IPCL V-3 → ESD (if <2 cm) or surgery
JES B3 / IPCL V-N → Surgery ± neoadjuvant therapy
3. Four morphological factors to assess in every lesion (DTCV):
- D - Dilation
- T - Tortuosity
- C - Caliber irregularity
- V - Variation in shape (non-uniformity)
3 or fewer factors = JES Type A (benign/low-grade)
All 4 factors = JES Type B (neoplastic) - then subclassify B1/B2/B3 by loop status and caliber
4. NBI technical note:
- NBI uses 415 nm (blue) and 540 nm (green) wavelengths
- These are absorbed preferentially by hemoglobin, enhancing visualization of superficial capillaries
- Magnification (x80-115) is required for accurate IPCL assessment